Table 2.
Adverse Reactions to COVID-19 Vaccines in Patients With IEI
| Author | Total number of patients with IEI | COVID-19 vaccine(s) | Serious reactions | Reactogenicity |
|---|---|---|---|---|
| Amodio et al41 | 21 | BNT162b2 | None | Fever 38%, myalgia 19%, malaise 14% |
| Antoli et al42 | 28 | BNT162B2, mRNA-1273, ChAdOx1 nCoV-19, Ad26.COV2.S | None | Most common was pain/redness/swelling at the injection site, and fever, more common after dose 2 |
| Arroyo-Sanchez et al43 | 18 | mRNA-1273, BNT162b2, ChAdOx1-S | None | NR |
| Bergman et al46 | 90 | BNT162b2 | 3, all unlikely related | Lower than HC |
| Bradley et al47 | 1 | BNT162b2 | None | Mild (flu like) |
| Delmonte et al36 | 81 | mRNA-1273, BNT162b2, Ad26.COV2.S | None | Mild-moderate systemic systems (fever, fatigue, myalgias) in 22% after D1, 53% after D2. |
| Goda et al48 | 30 | ChAdOx1 BNT162b2 Booster |
None | Increased local reaction compared with HC; otherwise comparable with HC |
| Hagin et al50 | 26 | BNT162b2 | None | 13 (50%): local pain (9), fever (3), adenopathy (1) |
| Oshiro et al53 | 1 | SinoVAC | None | None |
| Pham et al54 | 33 | mRNA-1273, BNT162b2 | None | Mild-moderate in 14 of 33 (42%) |
| Ponsford et al55 | 284 | mRNA-1273, BNT162b2, ChAdOx1-S | None | Not reported |
| Romano et al57 | 5 | mRNA-1273, BNT162b2 | None | Mild-moderate systems in 5 of 5 |
| Schultz-Cherry et al60 | 25 | mRNA-1273, BNT162b2 | None | Mild-moderate in 70% |
| Squire et al73 | 37 | mRNA-1273, BNT162b2, Coronavac, ChAdOx1-S, Ad26.COV2.S | None | Dose 1: 48% mild |
| Dose 2: 54% mild, 30.8% moderate, 15.4% severe | ||||
| van Leeuwen et al39 | 505 | mRNA-1273 | 9, including 1 patient with cerebral hemorrhage 2 mo post-vaccination, 1 with dyspnea, 1 with tinnitus | Not reported |
| Total | 1134 | 3 possibly related events | 38%-70% |
Abbreviations: COVID-19, coronavirus disease 2019; HC, healthy control; IEI, inborn errors of immunity; mRNA, messenger RNA; NR, not reported.